• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.

作者信息

Verma Subodh, Dhingra Nitish K, Bonaca Marc P, Butler Javed, Anker Stefan D, Ferreira João Pedro, Filippatos Gerasimos, Januzzi James L, Lam Carolyn S P, Sattar Naveed, Iwata Tomoko, Nordaby Matias, Brueckmann Martina, Pocock Stuart J, Packer Milton

机构信息

Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Canada (S.V., N.K.D.).

Division of Cardiology, CPC Clinical Research, University of Colorado School of Medicine, Aurora (M.P.B.).

出版信息

Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1334-1337. doi: 10.1161/ATVBAHA.123.319156. Epub 2023 May 18.

DOI:10.1161/ATVBAHA.123.319156
PMID:37199158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10281175/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/138d/10281175/c9d7fd64a5b9/atv-43-1334-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/138d/10281175/c9d7fd64a5b9/atv-43-1334-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/138d/10281175/c9d7fd64a5b9/atv-43-1334-g001.jpg

相似文献

1
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled.外周动脉疾病的存在与心力衰竭事件风险增加相关：来自EMPEROR汇总分析的见解。
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1334-1337. doi: 10.1161/ATVBAHA.123.319156. Epub 2023 May 18.
2
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
3
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.钠-葡萄糖协同转运蛋白2抑制剂：具有多种作用的药物，但哪一种与射血分数保留的心力衰竭相关？关于文章《恩格列净对射血分数保留的心力衰竭的早期获益：EMPEROR-Preserved试验的见解》的信函
Eur J Heart Fail. 2022 Jul;24(7):1323-1324. doi: 10.1002/ejhf.2466. Epub 2022 Mar 9.
4
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.心力衰竭与外周动脉疾病患者结局的相关性：EUCLID 的见解。
J Am Heart Assoc. 2021 Jun 15;10(12):e018684. doi: 10.1161/JAHA.120.018684. Epub 2021 May 31.
5
Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study.2型糖尿病及心力衰竭对预后的影响与其他心血管疾病的比较：一项全国性研究
Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006260. doi: 10.1161/CIRCOUTCOMES.119.006260. Epub 2020 Jun 23.
6
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭预防和治疗中的临床应用：超越 2 型糖尿病。一篇叙述性综述。
Adv Ther. 2022 Feb;39(2):845-861. doi: 10.1007/s12325-021-01989-z. Epub 2021 Dec 9.
7
The impact of peripheral arterial disease on patients with congestive heart failure.外周动脉疾病对充血性心力衰竭患者的影响。
Heart Fail Clin. 2014 Apr;10(2):327-38. doi: 10.1016/j.hfc.2013.10.006.
8
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭中的应用：一项随机临床试验的荟萃分析。
Am J Med. 2020 Nov;133(11):e625-e630. doi: 10.1016/j.amjmed.2020.04.006. Epub 2020 May 7.
9
Independent link between peripheral artery disease and muscle wasting in patients with heart failure.外周动脉疾病与心力衰竭患者肌肉减少症之间的独立关联。
ESC Heart Fail. 2020 Oct;7(5):3252-3256. doi: 10.1002/ehf2.12951. Epub 2020 Jul 28.
10
DAPA-HF study: Are the benefits uniform across non-diabetic subgroups.达格列净治疗射血分数降低的心力衰竭研究：非糖尿病亚组的获益是否一致？
Indian Heart J. 2020 Sep-Oct;72(5):469-470. doi: 10.1016/j.ihj.2020.08.012. Epub 2020 Aug 19.

引用本文的文献

1
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.钠-葡萄糖协同转运蛋白2抑制剂与动脉粥样硬化
Am J Prev Cardiol. 2025 Jul 18;23:101061. doi: 10.1016/j.ajpc.2025.101061. eCollection 2025 Sep.
2
Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.STRIDE试验的设计与基线特征：评估司美格鲁肽在有症状外周动脉疾病和2型糖尿病患者中的疗效
Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11;10(8):728-737. doi: 10.1093/ehjcvp/pvae071.
3
Paired Transcriptomic Analyses of Atheromatous and Control Vessels Reveal Novel Autophagy and Immunoregulatory Genes in Peripheral Artery Disease.

本文引用的文献

1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
2
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
3
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.卡格列净对 2 型糖尿病截肢风险的影响：CANVAS 项目。
动脉粥样硬化和对照血管的配对转录组分析揭示了外周动脉疾病中新型自噬和免疫调节基因。
Cells. 2024 Jul 28;13(15):1269. doi: 10.3390/cells13151269.
4
Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review.2型糖尿病患者外周动脉疾病的流行病学与负担：一项系统文献综述
Diabetes Ther. 2024 Sep;15(9):1893-1961. doi: 10.1007/s13300-024-01606-6. Epub 2024 Jul 18.
5
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review PART II-Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory.老年患者的非冠状动脉外周动脉粥样硬化疾病（颈动脉、肾动脉、下肢）——综述 第二部分——冠状动脉以外区域外周动脉粥样硬化病变老年患者的药物治疗方法
J Clin Med. 2024 Mar 5;13(5):1508. doi: 10.3390/jcm13051508.
6
BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally.最佳慢性肢体威胁性缺血国际协作组：为全球慢性肢体威胁性缺血患者规划更美好的未来。
Br J Surg. 2024 Jan 31;111(2). doi: 10.1093/bjs/znad413.
Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.
4
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).依洛尤单抗降低低密度脂蛋白胆固醇水平及外周动脉疾病患者的结局：来自 FOURIER 试验（在高风险人群中用 PCSK9 抑制剂进行进一步心血管结局研究）的见解。
Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13.
5
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.利伐沙班联合或不联合阿司匹林用于稳定型心血管疾病。
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.